Diabetes
Here you’ll find clinical education, patient educational resources, product information and product samples to help you manage care for patients with diabetes.
Explore diabetes
Obesity
Access clinical education, patient educational resources, and product information to support patients with obesity.
Explore obesity
Non-US Health Care Professionals
Prescribing Information | Important Safety Information
Saxenda® is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with a BMI ≥30 kg/m2, or ≥27 kg/m2 with one or more weight-related comorbidities, and for patients aged 12-17 years with body weight above 60 kg (132 lbs) and initial BMI of ≥30 kg/m2 for adults.
Click for Limitations of Use.

A comprehensive weight-management support program for patients

Actor portrayal

Actor portrayal

Logo for SaxendaCare®, automatically enrolled when patients activate a Saxenda® (liraglutide) injection 3 mg Savings Card. This helps patients learn scientifically proven weight loss and maintenance strategies through personalized coaching, helpful emails, phone support, and more

SaxendaCare® helps to empower your patients

Enrolled patients learn scientifically proven weight-loss and maintenance strategies through personalized coaching, helpful emails, phone support and more.

Saxenda® (liraglutide) injection 3 mg logo for the treatment of obesity

Patients can call
1-877-304-6894 anytime with questions about Saxenda®  

Saxenda® Welcome Kit

Getting your patients off to a good start begins with a Saxenda® Welcome Kit. They’ll receive a Welcome Letter and portion plate, plus a Health and Wellness guide—all mailed right to their home.

Logo for the SaxendaCare® Welcome Kit, including a welcome letter and portion plate and a health and wellness guide
Icon of a stamped addressed envelope, representing the SaxendaCare® Welcome Letter (downloadable pdf)

Welcome letter

Logo of a book with a heart on the cover, representing the SaxendaCare® Health and Wellness Guide, which emphasizes that pharmacotherapy is not a replacement for diet and lifestyle interventions for weight loss

Health and Wellness guide

Logo of an apple on a scale, representing the Portion Plate that patients receive when they enroll in SaxendaCare®, to emphasize that pharmacotherapy is not a replacement for diet and lifestyle interventions for weight loss

Portion plate

SaxendaCare® coaching options

Newly enrolled SaxendaCare® members can choose to receive support, either through Noom, a weight-loss application and personalized meal-planning service, or through live phone calls with SaxendaCare® coaches.

App-based support, powered by Noom

Logo of a hand holding a smartphone that has a weight loss coaching app
Logo for Noom®, which offers a coaching app for weight loss
  • Full access to Noom’s interactive content, recipes and tracking tools for calories, exercise and more
  • Personalized plan tailored to fit individual lifestyles
  • Virtual 1:1 and group support
  • Dynamic support system through in-app messaging, designed to keep patients motivated

Live phone calls with SaxendaCare® coaches

Logo representing SaxendaCare® coaches, who are registered dietitians certified in weight management. Patients enrolled in SaxendaCare® can call these coaches for help with SaxendaCare® and goal setting
  • SaxendaCare® coaches are registered dietitians, certified in weight management
  • Enrolled patients can call their coaches for help with SaxendaCare® and goal setting
  • Coaches help patients with accountability and questions they may have along the way

Comprehensive skill-building curriculum

Emails guide patients through a skill-building curriculum that can help lead to positive behavior change.

Actor portrayal

Weekly email topics include:

  • Pen training
  • Dosing schedule
  • Reminders about dosing and refills
  • Focusing on short-term goals
  • Celebrating the small steps
  • Finding support

Actor portrayal

Weekly email topics include:

  • Making small changes
  • Setting goals and expectations
  • Identifying motivations
  • Finding creative ways to stay on track
  • Experiencing setbacks
  • Rewards for progress made

Actor portrayal

Weekly email topics include:

  • Understanding negative self-talk
  • Introducing the plate method
  • Building a healthy, balanced meal, including controlling portions and cutting calories
  • Fiber, fresh fruit and vegetables, and choosing foods with good fats

Actor portrayal

Weekly email topics include:

  • Different kinds of physical activity
  • Aerobic exercise, resistance training and flexibility training
  • Fitting activity into each day
  • Scheduling time for being active and having a support system
Image of people standing in a V-formation, representing patients who used a Saxenda® Savings Card and enrolled in SaxendaCare®

Actor portrayal

Actor portrayal

Patients enrolled in award-winning SaxendaCare® are more adherent to therapy than those who are not enrolled.1,a

aBased on a Crossix analysis (December 2019); patients enrolled in SaxendaCare® filled more prescriptions vs those who were not enrolled.

Resources for your patients

Prescribing Information | Important Safety Information
(1:23)

Prescription savings card

Saxenda® (liraglutide) injection 3 mg Savings Card

Help eligible patients access the prescription savings card option we offer.

Reference

  1. Data on file. Novo Nordisk Inc; Plainsboro, NJ.

Important Safety Information for Saxenda® (liraglutide) injection 3 mg

WARNING: RISK OF THYROID C-CELL TUMORS
Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Saxenda® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. Saxenda® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of Saxenda® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Saxenda®.

Indications and Usage

Saxenda® (liraglutide) injection 3 mg is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:
  • Adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia)
  • Pediatric patients aged 12 years and older with body weight above 60 kg (132 lbs) and initial BMI corresponding to 30 kg/m2 or greater for adults (obese) by international cut-offs
Limitations of Use
  • Saxenda® contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist.
  • The safety and effectiveness of Saxenda® in pediatric patients with type 2 diabetes have not been established.
  • The safety and effectiveness of Saxenda® in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information cont.

Contraindications

Saxenda® is contraindicated in:

  • Patients with a personal or family history of MTC or patients with MEN 2.
  • Patients with a prior serious hypersensitivity reaction to liraglutide or to any of the excipients in Saxenda®.
  • Pregnancy.
Warnings and Precautions
  • Risk of Thyroid C-cell Tumors: If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide postmarketing. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Saxenda® promptly and if pancreatitis is confirmed, do not restart.
  • Acute Gallbladder Disease: Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in patients treated with Saxenda® than with placebo even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
  • Hypoglycemia: Adult patients with type 2 diabetes on an insulin secretagogue (eg, a sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia with use of Saxenda®. The risk may be lowered by a reduction in the dose of insulin secretagogues or insulin. In pediatric patients without type 2 diabetes, hypoglycemia occurred. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms.
  • Heart Rate Increase: Mean increases in resting heart rate of 2 to 3 beats per minute (bpm) were observed in patients treated with Saxenda®. Monitor heart rate at regular intervals and inform patients to report palpitations or feelings of a racing heartbeat while at rest during treatment with Saxenda®. Discontinue Saxenda® in patients who experience a sustained increase in resting heart rate.
  • Renal Impairment: Acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis, have been reported, usually in association with nausea, vomiting, diarrhea, or dehydration. Use caution when initiating or escalating doses of Saxenda® in patients with renal impairment.
  • Hypersensitivity Reactions: Serious hypersensitivity reactions (eg, anaphylaxis and angioedema) have been reported in patients treated with liraglutide. If a hypersensitivity reaction occurs, patients should stop taking Saxenda® and promptly seek medical advice.
  • Suicidal Behavior and Ideation: In adult clinical trials, 9 (0.3%) of 3,384 patients treated with Saxenda® and 2 (0.1%) of the 1,941 treated with placebo reported suicidal ideation; one of the Saxenda® treated patients attempted suicide. In a pediatric trial, 1(0.8%) of the 125 Saxenda® treated patients died by suicide. There was insufficient information to establish a causal relationship to Saxenda®. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue treatment if patients experience suicidal thoughts or behaviors. Avoid Saxenda® in patients with a history of suicidal attempts or active suicidal ideation.
Adverse Reactions
  • The most common adverse reactions, reported in ≥5% are nausea, diarrhea, constipation, vomiting, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis.
Drug Interactions
  • Saxenda® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor for potential consequences of delayed absorption of oral medications concomitantly administered with Saxenda®.
Use in Specific Populations
  • There are no data on the presence of liraglutide in human breast milk; liraglutide was present in the milk of lactating rats.
  • Saxenda® has not been studied in patients less than 12 years of age.
  • Saxenda® slows gastric emptying. Saxenda® has not been studied in patients with preexisting gastroparesis.

Please click here for Saxenda® Prescribing Information, including Boxed Warning.